Publication: Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities
Issued Date
2021-12-24
Resource Type
ISSN
2296858X
Other identifier(s)
2-s2.0-85122435997
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Frontiers in Medicine. Vol.8, (2021)
Suggested Citation
Wararat Chiangjong, Pukkavadee Netsirisawan, Suradej Hongeng, Somchai Chutipongtanate Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities. Frontiers in Medicine. Vol.8, (2021). doi:10.3389/fmed.2021.761362 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/77395
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities
Other Contributor(s)
Abstract
Recently, red blood cell-derived extracellular vesicles (RBCEVs) have attracted attention for clinical applications because of their safety and biocompatibility. RBCEVs can escape macrophages through the binding of CD47 to inhibitory receptor signal regulatory protein α. Furthermore, genetic materials such as siRNA, miRNA, mRNA, or single-stranded RNA can be encapsulated within RBCEVs and then released into target cells for precise treatment. However, their side effects, half-lives, target cell specificity, and limited large-scale production under good manufacturing practice remain challenging. In this review, we summarized the biogenesis and composition of RBCEVs, discussed the advantages and disadvantages of RBCEVs for drug delivery compared with synthetic nanovesicles and non-red blood cell-derived EVs, and provided perspectives for overcoming current limitations to the use of RBCEVs for clinical applications.